Brief: Argenx Says Phase 3 ALKIVIA Study Met Its Primary Endpoint
19/10/2026 13:06
BRIEF-Argenx Says Phase 3 ALKIVIA Study Met Its Primary Endpoint Oct 19 (Reuters) - argenx SE ARGX.BR:
TO PRESENT PHASE 3 ALKIVIA RESULTS IN AUTOIMMUNE MYOSITIS AS A LATE-BREAKING ORAL PRESENTATION AT ACR CONVERGENCE 2026
ALKIVIA PROVIDES FIRST PHASE 3 EVIDENCE THAT PRECISELY TARGETING FCRN WITH EFGARTIGIMOD CAN DELIVER CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS LIVING WITH AUTOIMMUNE MYOSITIS
PHASE 3 ALKIVIA STUDY MET ITS PRIMARY ENDPOINT
Source text: ID:nGNEbvgjVg
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))